Literature DB >> 17909004

Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism.

Gang Chen1, Andrea S Blevins-Primeau, Ryan W Dellinger, Joshua E Muscat, Philip Lazarus.   

Abstract

Nicotine, the major addicting agent in tobacco and tobacco smoke, undergoes a complex metabolic pathway, with approximately 22% of nicotine urinary metabolites in the form of phase II N-glucuronidated compounds. Recent studies have shown that UGT2B10 is a major enzyme involved in the N-glucuronidation of several tobacco-specific nitrosamines. In the present study, microsomes of UGT2B10-overexpressing HEK293 cells exhibited high N-glucuronidation activity against both nicotine and cotinine with apparent KM's that were 37- and 3-fold lower than that observed for microsomes of UGT1A4-overexpressing cells against nicotine and cotinine, respectively. The KM of microsomes from wild-type (WT) UGT2B10-overexpressing cells for nicotine and cotinine was similar to that observed for human liver microsomes (HLM) against both substrates. The level of glucuronidated nicotine or cotinine in 112 HLM samples was correlated with UGT2B10 genotype; the levels of nicotine- and cotinine-glucuronide were 21% to 30% lower in specimens from subjects with the UGT2B10 (*1/*2) genotype compared with specimens from subjects with the WT UGT2B10 (*1/*1) genotype; a 5- and 16-fold lower level of nicotine- and cotinine-glucuronide formation, respectively, was observed in HLM from subjects with the UGT2B10 (*2/*2) genotype. In contrast to the relatively high activity observed for cells overexpressing WT UGT2B10 in vitro, little or no glucuronidation was observed for microsomes from cells overexpressing the UGT2B10*2 variant against either nicotine or cotinine. These data suggest that UGT2B10 is the major hepatic enzyme involved in nicotine/cotinine glucuronidation and that the UGT2B10*2 variant significantly reduces nicotine- and cotinine-N-glucuronidation formation and plays an important role in nicotine metabolism and elimination.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17909004     DOI: 10.1158/0008-5472.CAN-07-2245

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption.

Authors:  Jeannette Zinggeler Berg; Linda B von Weymarn; Elizabeth A Thompson; Katherine M Wickham; Natalie A Weisensel; Dorothy K Hatsukami; Sharon E Murphy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

2.  Low Cotinine Glucuronidation Results in Higher Serum and Saliva Cotinine in African American Compared to White Smokers.

Authors:  Sharon E Murphy; Christopher J Sipe; Kwangsoo Choi; Leah M Raddatz; Joseph S Koopmeiners; Eric C Donny; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-03-06       Impact factor: 4.254

3.  Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.

Authors:  Kathryn Kelly Erickson-Ridout; Junjia Zhu; Philip Lazarus
Journal:  Pharmacogenet Genomics       Date:  2011-09       Impact factor: 2.089

4.  Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms.

Authors:  Gang Chen; Nino E Giambrone; Douglas F Dluzen; Joshua E Muscat; Arthur Berg; Carla J Gallagher; Philip Lazarus
Journal:  Cancer Res       Date:  2010-09-28       Impact factor: 12.701

5.  Regulation of UDP-glucuronosyltransferase 1A1 expression and activity by microRNA 491-3p.

Authors:  Douglas F Dluzen; Dongxiao Sun; Anna C Salzberg; Nate Jones; Ryan T Bushey; Gavin P Robertson; Philip Lazarus
Journal:  J Pharmacol Exp Ther       Date:  2014-01-07       Impact factor: 4.030

6.  Predictors of smoking reduction among Blacks.

Authors:  Carla J Berg; Janet L Thomas; Hongfei Guo; Lawrence C An; Kolawole S Okuyemi; Tracie C Collins; Jasjit S Ahluwalia
Journal:  Nicotine Tob Res       Date:  2010-03-01       Impact factor: 4.244

Review 7.  Biomarkers of exposure to new and emerging tobacco delivery products.

Authors:  Suzaynn F Schick; Benjamin C Blount; Peyton Jacob; Najat A Saliba; John T Bernert; Ahmad El Hellani; Peter Jatlow; R Steven Pappas; Lanqing Wang; Jonathan Foulds; Arunava Ghosh; Stephen S Hecht; John C Gomez; Jessica R Martin; Clementina Mesaros; Sanjay Srivastava; Gideon St Helen; Robert Tarran; Pawel K Lorkiewicz; Ian A Blair; Heather L Kimmel; Claire M Doerschuk; Neal L Benowitz; Aruni Bhatnagar
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-05-18       Impact factor: 5.464

8.  UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers.

Authors:  Catherine A Wassenaar; David V Conti; Soma Das; Peixian Chen; Edwin H Cook; Mark J Ratain; Neal L Benowitz; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-02       Impact factor: 4.254

9.  Association between Glucuronidation Genotypes and Urinary NNAL Metabolic Phenotypes in Smokers.

Authors:  Gang Chen; Shaman Luo; Shannon Kozlovich; Philip Lazarus
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-05-09       Impact factor: 4.254

10.  Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype.

Authors:  Jeannette Zinggeler Berg; Jesse Mason; Angela J Boettcher; Dorothy K Hatsukami; Sharon E Murphy
Journal:  J Pharmacol Exp Ther       Date:  2009-09-28       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.